ATLN (Atlantic International) Debt-to-Asset : 0.67 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Atlantic International Debt-to-Asset?

Atlantic International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $45.2 Mil. Atlantic International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $37.5 Mil. Atlantic International's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $122.8 Mil. Atlantic International's debt to asset for the quarter that ended in Dec. 2024 was 0.67.

Atlantic International Debt-to-Asset Historical Data

The historical data trend for Atlantic International's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atlantic International Debt-to-Asset Chart

Atlantic International Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

5.13

0.13

0.35

1.12

0.67

Atlantic International Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															1.12	0.86	0.61	0.61	0.67

Competitive Comparison of Atlantic International's Debt-to-Asset

For the Diagnostics & Research subindustry, Atlantic International's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atlantic International's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Atlantic International's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Atlantic International's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Atlantic International Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Atlantic International's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(45.197	+	37.519)	/	122.752
	=	0.67

Atlantic International's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(45.197	+	37.519)	/	122.752
	=	0.67

Atlantic International (NAS:ATLN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Atlantic International Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Atlantic International's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Atlantic International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (NAS:ATLN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Federal Street, Billerica, MA, USA, 01821

Website

http://www.seqll.com

Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.

Executives

Daniel Robert Jones	officer: President, CEO	317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer	director	464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally	officer: CHIEF FINANCIAL OFFICER	66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy	officer: CFO, Secretary	166 WINN STREET, WOBURN MA 01801